STENTiT Enrolls First Patient in Clinical Trial Evaluating a Novel Stent with Regenerative Properties to Support Limb Preservation
EINDHOVEN, The Netherlands – June 26, 2025 – STENTiT, a pioneering medical device company, developing a novel class of stents with regenera6ve proper6es, today announced the successful implanta6on of its Resorbable Fibrillated Scaffold (RFS). As part of the VITAL-IT 1 study, pa6ents with chronic limb-threatening ischemia (CLTI) below-the-knee, have successfully been treated using the RFS implant. In this clinical procedure, revasculariza6on was achieved using an endovascular approach to restore the blood flow to the foot STENTiT’s RFS device is a bioresorbable stent built from microfibers, providing structural support to instantly open, and facilitate the reconstruc6on of the artery. Due to the porous design of the implant, pa6ent’s own cells infiltrate into the mesh, triggering the forma6on of new vascular 6ssue. While the artery is being reconstructed from the inside-out, the synthe6c implant gradually resorbs and ul6mately disappears over 6me.
